Hyperglycemia modulates extracellular amyloid-β concentrations and neuronal activity in vivo.

Epidemiological studies show that patients with type 2 diabetes (T2DM) and individuals with a diabetes-independent elevation in blood glucose have an increased risk for developing dementia, specifically dementia due to Alzheimer's disease (AD). These observations suggest that abnormal glucose metabolism likely plays a role in some aspects of AD pathogenesis, leading us to investigate the link between aberrant glucose metabolism, T2DM, and AD in murine models. Here, we combined two techniques – glucose clamps and in vivo microdialysis – as a means to dynamically modulate blood glucose levels in awake, freely moving mice while measuring real-time changes in amyloid-β (Aβ), glucose, and lactate within the hippocampal interstitial fluid (ISF). In a murine model of AD, induction of acute hyperglycemia in young animals increased ISF Aβ production and ISF lactate, which serves as a marker of neuronal activity. These effects were exacerbated in aged AD mice with marked Aβ plaque pathology. Inward rectifying, ATP-sensitive potassium (K(ATP)) channels mediated the response to elevated glucose levels, as pharmacological manipulation of K(ATP) channels in the hippocampus altered both ISF Aβ levels and neuronal activity. Taken together, these results suggest that K(ATP) channel activation mediates the response of hippocampal neurons to hyperglycemia by coupling metabolism with neuronal activity and ISF Aβ levels.

[1]  Eric D. Vidoni,et al.  Impaired glycemia increases disease progression in mild cognitive impairment , 2014, Neurobiology of Aging.

[2]  Tzeng-Ji Chen,et al.  Diabetes Mellitus and the Risk of Alzheimer’s Disease: A Nationwide Population-Based Study , 2014, PloS one.

[3]  S. Haneuse,et al.  Glucose levels and risk of dementia. , 2013, The New England journal of medicine.

[4]  S. Craft,et al.  Insulin and Alzheimer's disease: untangling the web. , 2012, Journal of Alzheimer's disease : JAD.

[5]  Adam W. Bero,et al.  Disruption of the Sleep-Wake Cycle and Diurnal Fluctuation of β-Amyloid in Mice with Alzheimer’s Disease Pathology , 2012, Science Translational Medicine.

[6]  S. Craft Alzheimer disease: Insulin resistance and AD—extending the translational path , 2012, Nature Reviews Neurology.

[7]  S. M. de la Monte Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimer's Disease , 2012, Current Alzheimer research.

[8]  Pierre J Magistretti,et al.  Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. , 2011, Cell metabolism.

[9]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[10]  J. Morris,et al.  Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.

[11]  Jee Hoon Roh,et al.  Neuronal activity regulates the regional vulnerability to amyloid-β deposition , 2011, Nature Neuroscience.

[12]  Yan Wang,et al.  Characterizing the Appearance and Growth of Amyloid Plaques in APP/PS1 Mice , 2009, The Journal of Neuroscience.

[13]  T. Uehara,et al.  Lactate production and neurotransmitters; evidence from microdialysis studies , 2008, Pharmacology Biochemistry and Behavior.

[14]  Guojun Bu,et al.  Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In Vivo , 2008, Neuron.

[15]  Sheng-Nan Wu,et al.  Glucose and hippocampal neuronal excitability: Role of ATP‐sensitive potassium channels , 2007, Journal of neuroscience research.

[16]  Suzanne Craft,et al.  Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. , 2007, Current Alzheimer research.

[17]  Colin G. Nichols,et al.  KATP channels as molecular sensors of cellular metabolism , 2006, Nature.

[18]  Steven Mennerick,et al.  Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo , 2005, Neuron.

[19]  Joanna L. Jankowsky,et al.  Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase , 2004 .

[20]  D. Holtzman,et al.  In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life , 2003, The Journal of Neuroscience.

[21]  A Hofman,et al.  Diabetes mellitus and the risk of dementia , 1999, Neurology.

[22]  N. Rawson,et al.  Distribution and phenotype of neurons containing the ATP-sensitive K+ channel in rat brain , 1998, Brain Research.

[23]  R. Shulman,et al.  Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Magistretti,et al.  Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[26]  S. Monte Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimer's Disease , 2012 .

[27]  M. Mattson,et al.  The KATP channel activator diazoxide ameliorates amyloid-β and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[28]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[29]  D. Borchelt,et al.  Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. , 2004, Human molecular genetics.